Ubikare

Ubikare

Private
BilbaoHealthcare & Life Scienceshttps://ubikare.io/

Last Round

VC Round

Jan 28, 2022

Total Funding Raised

$280,000

Momentum Score

25 /100

Company Overview

Ubikare is a health-tech company that provides a software platform, NAIHA (Natural & Artificial Intelligence Health Assistant), and in-home socio-sanitary services for the elderly and dependents.

Sector

Healthcare & Life Sciences

Verticals

Vertical SaaS, Medical AI, Telemedicine, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Subscription SaaS, Government Contracts, Services & Consulting

AI Layer

Application

Keywords

AI health assistantelderly care softwareclinical decision supportcare platformClass IIa medical deviceAgeTechhome hospitalizationHealthTechadvanced telemedicinechronic care managementclinical trial softwarehome care softwarecare automationintegrated health dataB2G healthcarepersonalized care planscontract research organizationCROCareTech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ubikare Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ubikare Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 28, 2022
StrategicSep 21, 2021
SeedJul 14, 2020

Key People

Founding team and executive leadership

Egoitz Arruti

CTO

Executive Team

Ubikare Investors

Notable investors and investment history

InvestorRounds
Mutua VenturesStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 14, 2026

    Partnered with Vicomtech and Multiverse Computing on Q-CLINIC initiative.

  • Apr 14, 2026

    Launched Q-CLINIC, applying quantum algorithms to clinical data management.

Ubikare Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ubikare Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ubikare's valuation, stock price, and market status.

Firmographic Details

HeadquartersBilbao
Employee Range47
Year Founded2016
Last FundingJan 28, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.